Skip to content

Artificial intelligence lesion marking system assisted endoscopic submucosal dissection for the treatment of esophageal mucosal lesions:A prospective cohort study

Artificial intelligence lesion marking system assisted endoscopic submucosal dissection for the treatment of esophageal mucosal lesions:A prospective cohort study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040072
Enrollment
Unknown
Registered
2020-11-20
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal mucosal lesions

Interventions

examination&#32
with&#32
artificial&#32
intelligence&#32
system

Sponsors

Shanghai Xuhui District Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) aged greater than 18 years old; (2) The patients who were diagnosed as esophageal mucosal lesions before operation and were suitable for ESD, that is, the lesions were limited to the mucosal layer or infiltrated into the submucosa within 200 um (SM1); (3) Imaging examination showed no distant metastasis; (4) Without other organic esophageal diseases; (5) One lesion at a time; (6) Patients or family members, who can understand the research plan and are willing to participate in this research, provide written informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with organic esophageal diseases; (2) Patients with recurrent esophageal cancer; (3) Patients with a history of previous esophageal disease surgery, which may affect the outcome of this surgery; (4) Pregnant or breastfeeding women; (5) The American Society of Anesthesiologists (ASA) grade is greater than grade III and cannot tolerate anesthesia and surgery; (6) Patients transferred to surgery; (7) Postoperative pathology shows that the depth of infiltration of the lesion exceeds SM1, or is poorly differentiated, undifferentiated cancer and requires additional surgery; (8) Patient or family members cannot understand the conditions and goals of this study.

Design outcomes

Primary

MeasureTime frame
Positive rate of surgical specimen level margin;Postoperative recurrence rate;

Secondary

MeasureTime frame
En bloc resection rate;Complete resection rate;operation time;Surgical specimen size;Additional surgery rate;

Countries

China

Contacts

Public ContactYunshi Zhong

Zhongshan Hospital affiliated to Fudan University

zhong.yunshi@zs-hospital.sh.cn+86 13564623481

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026